Catalyst fails to mollify Bernie Sanders over rare-disease drug price- STAT

Catalyst fails to mollify Bernie Sanders over rare-disease drug price- STAT

More reads

• Catalyst fails to mollify an angry Bernie Sanders over the price of its rare disease drug. (STAT Plus)
• Mereo BioPharma withdraws its $70 million U.S. IPO. (Nasdaq)
• Drug giant Merck acquires Seattle biotech Immune Design for $300 million. (Puget Sound Business Journal)
• Purdue’s Sackler embraced plan to conceal OxyContin’s strength from doctors, sealed deposition shows. (STAT)